ABSTRACT
NF-κB is dually involved in neurogenesis and brain pathology. Here, we addressed its role in adult axoneogenesis by generating mutations of RelA (p65) and p50 (also known as NFKB1) heterodimers of canonical NF-κB. In addition to RelA activation in astrocytes, optic nerve axonotmesis caused a hitherto unrecognized induction of RelA in growth-inhibitory oligodendrocytes. Intraretinally, RelA was induced in severed retinal ganglion cells and was also expressed in bystander Müller glia. Cell-type-specific deletion of transactivating RelA in neurons and/or macroglia stimulated axonal regeneration in a distinct and synergistic pattern. By contrast, deletion of the p50 suppressor subunit promoted spontaneous and post-injury Wallerian degeneration. Growth effects mediated by RelA deletion paralleled a downregulation of growth-inhibitory Cdh1 (officially known as FZR1) and upregulation of the endogenous Cdh1 suppressor EMI1 (officially known as FBXO5). Pro-degenerative loss of p50, however, stabilized retinal Cdh1. In vitro, RelA deletion elicited opposing pro-regenerative shifts in active nuclear and inactive cytoplasmic moieties of Cdh1 and Id2. The involvement of NF-κB and cell-cycle regulators such as Cdh1 in regenerative processes of non-replicative neurons suggests novel mechanisms by which molecular reprogramming might be executed to stimulate adult axoneogenesis and treat central nervous system (CNS) axonopathies.
Footnotes
↵‡ Present address: Georg August University, Bernstein Focus Neurotechnology (BFNT) and Johann Friedrich Blumenbach Institute for Zoology and Anthropology, Berliner Strasse 28, 37073 Göttingen, Germany.
Competing interests
The authors declare no competing interests.
Author contributions
R.H. and A.K. organized the study and prepared the manuscript. K.-H.H. developed the MEMRI protocol. K.K. and K.-F.S. conducted the functional animal tasks. C.E. performed cell culture experiments. K.-A.N. provided the Cre line for the creation of ODC-specific mouse mutants. F.W., O.W.W., S.L. and J.R.R. supervised and financed the study and helped with data interpretation.
Funding
R.H. is supported by the VELUX Foundation (Switzerland; grant number 806); A.K. was supported by the Interdisziplinäres Zentrum für Klinische Forschung (IZKF), Jena, and the Oppenheim-Foundation/Novartis.
Supplementary material available online at http://jcs.biologists.org/lookup/suppl/doi:10.1242/jcs.140731/-/DC1
- Received August 15, 2013.
- Accepted May 8, 2014.
- © 2014. Published by The Company of Biologists Ltd